See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
MIC determinations for cefiderocol using broth microdilution can be affected by Mueller–Hinton broth manufacturer source, but not by their media lots
MIC determinations for cefiderocol using broth microdilution can be affected by Mueller–Hinton broth manufacturer source, but not by their media lots
New onset conditions, exacerbations and worsening of underlying conditions following COVID-19 infection
New onset conditions, exacerbations and worsening of underlying conditions following COVID-19 infection
Open-label phase 2 study of single and multiple doses of cefiderocol in hospitalised infants aged less than 3 months with suspected/confirmed aerobic Gram-negative bacterial infections
Open-label phase 2 study of single and multiple doses of cefiderocol in hospitalised infants aged less than 3 months with suspected/confirmed aerobic Gram-negative bacterial infections
Outcomes of patients treated with cefiderocol for infections caused by β-lactam–β-lactamase inhibitor non-susceptible bacteria: subgroup analysis of the PROVE study
Outcomes of patients treated with cefiderocol for infections caused by β-lactam–β-lactamase inhibitor non-susceptible bacteria: subgroup analysis of the PROVE study
Pharmacodynamic assessment of combination of cefiderocol with xeruborbactam in murine thigh infection model
Pharmacodynamic assessment of combination of cefiderocol with xeruborbactam in murine thigh infection model
Pharmacokinetics, safety and tolerability of cefiderocol in paediatric patients aged 3 months to <18 years with suspected or confirmed gram-negative bacterial infections: results of the phase 1b–2 APEKS-PEDI study
Pharmacokinetics, safety and tolerability of cefiderocol in paediatric patients aged 3 months to <18 years with suspected or confirmed gram-negative bacterial infections: results of the phase 1b–2 APEKS-PEDI study
You Are Viewing Congress Locations
ASM Microbe 2026
ESPID 2026
AAN 2026
ESCMID 2026
CROI 2026
GSA 2025
APCCMI 2025
ASCP 2025
NACFC 2025
IDWeek 2025
AVG and IMRP 2025
ASM Microbe 2025
ESCMID 2025
ISIRV 2025
CROI 2025
SCCM 2025
IDWeek 2024
